Nkarta, Inc. — Director's Dealing 2020

Jul 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nkarta, Inc. (NKTX)
CIK: 0001787400
Period of Report: 2020-07-14

Reporting Person: GLAXOSMITHKLINE PLC (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-14	Common Stock	C	79090	—	Acquired	79090	Indirect
2020-07-14	Common Stock	C	525499	—	Acquired	604589	Indirect
2020-07-14	Common Stock	C	1712810	—	Acquired	2317399	Indirect
2020-07-14	Common Stock	P	833333	$18.00	Acquired	3150732	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-14	Series A Preferred Stock	$	C	292663	Disposed		Common Stock (79090)	Indirect
2020-07-14	Series A Preferred Stock	$	C	1994348	Disposed		Common Stock (525499)	Indirect
2020-07-14	Series B Preferred Stock	$	C	6337403	Disposed		Common Stock (1712810)	Indirect
2020-07-14	Stock Option (right to buy)	$18	A	10700	Acquired	2030-07-08	Common Stock (10700)	Indirect

Footnotes

F1: The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares reported herein are held by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.

F3: The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.

F4: The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F5: S.R. One, Limited purchased 833,333 shares of Common Stock of Nkarta, Inc. (the "Issuer") in connection with the Issuer's public offering.

F6: The stock option was granted to Simeon J. George as director's compensation and it vests 100% on the first anniversary of July 9, 2020, or, if earlier, on the day immediately preceding the first annual meeting of the Issuer's stockholders in 2021 at which one or more members of the Issuer's board of directors are to be elected. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Simeon George's separation from service with the Issuer due to death or "disability" (as described in the applicable award agreement).

F7: (continued from footnote 6) As Chief Executive Officer, President and a Member of the Board of Trustees at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, Simeon J. George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.